Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Viva BioInnovator
Shanghai, Shanghai, Chinavivabioinnovator.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Viva BioInnovator does not directly conduct clinical trials but has invested in and incubated numerous early-stage biotech startups. Portfolio highlights include DTx Pharma’s FALCON™ platform for siRNA delivery with preclinical programs targeting Charcot-Marie-Tooth Disease Type 1A and other neuromuscular/CNS indications. Some portfolio assets have reached FDA Orphan Drug Designation or been acquired by major pharma.
- Therapeutic areas
- Multiple
- Modalities
- Small moleculeMonoclonal antibodyAntibody-drug conjugateRNA therapyGene therapy
- Industry
- Investors
02
Partnerships
Partnerships with global biotechs through investment/incubation modelAccess to CRO/CDMO services via parent company
Beyond the preview
Go deeper on Viva BioInnovator.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Viva BioInnovator.